They have already had activation. They will have a
Post# of 72440
I think going forward on B without a partner could benefit them. They can do large study with very diverse population and show that drug is efficacious at low dose for multiple grades of infection without causing acute hypertensive episodes. Once they've proven that side effect to be of no concern, to not be found in higher rates than it is in the nontreated public, then they will have better bargaining position for partnership deal.
I doubt we'll see NASDAQ any time soon. Wish Leo hadn't mentioned it. Waldo will have to be clearly and transparently seen in order for them to move on uplist!